Isis Pharma Q3 Loss Narrows - Quick Facts

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) reported a narrower loss for the third-quarter, mirroring increase in revenues. The results of the third quarter 2013 also included a tax benefit of $5.2 million, compared with $0.7 million last year.

For the three-month period, net loss was $24.6 million or $0.21 per share, compared with $37.6 million or $0.37 per share last year. On average, eleven analysts polled by Thomson Reuters expected the company to report loss per share of $0.27 for the quarter. Analysts' estimates typically exclude one-time items.

Total revenues were $23.5 million, compared with $11.6 million a year ago. Analysts expected the company to generate revenues of $19.82 million for the quarter. Research and development revenue under collaborative agreements were $23.3 million, compared with $11.1 million last year.